#REVB

1 month ago

#REVB Comes to Agreement with FDA buff.ly/UcrG1MV

0 0 0 0

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. The reverse stock split will be effective as of

1 month ago

#REVB Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain

1 month ago

#REVB Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

1 month ago

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains — Intel, CSX In Focus - SPDR S&P 500 (ARCA:SPY) US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP exceeds estimates.

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus US stock futures slightly down after 2 days of gains. Trump withdraws ...

#BAH #COF #CSX #Earnings #Equities #Market #Summary #QQQ #REVB #SPY #Futures

Origin | Interest | Match

0 0 0 0

Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint -SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing

1 month ago

#REVB Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

1 month ago

#REVB: 2026 Shaping Up to be Great Year buff.ly/bFh0zTL

0 0 0 0

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development Revelation Biosciences (NASDAQ:REVB) announced the initiation of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies. The manufacturing run will provide clinical drug supply needed to support randomized, double‑blind, placebo‑controlled trials and is described as a critical step toward advancing GEMINI's development and approval pathway.The company said it is working with a leading global contract manufacturing organization and noted it met with the FDA in December 2025 to seek agency feedback on the clinical development and regulatory pathway for GEMINI as a treatment for acute kidney injury (AKI); Revelation is awaiting the FDA meeting minutes.

2 months ago

#REVB Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

3 months ago

#REVB Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission and acceptance of the end-of-phase 1 meeting

3 months ago

#REVB Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

4 months ago

#REVB Ready to Advance Groundbreaking Treatment buff.ly/SaUKYZ0

0 0 0 0

4 months ago

#REVB Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date Revelation Biosciences (NASDAQ:REVB) announced the cancellation of the adjourned Special Meeting of Stockholders that had been rescheduled for October 29, 2025 due to a technical difficulty that prevented stockholders from voting all of their shares.The company set a new record date of October 29, 2025 and scheduled a new Special Meeting for December 3, 2025. Revelation will mail new proxy materials to all stockholders of record as of the new record date and urges stockholders to vote promptly upon receipt.

4 months ago

#REVB Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 Revelation Biosciences (NASDAQ:REVB) announced that its 2025 Special Meeting of Stockholders originally convened on October 15, 2025 was adjourned due to insufficient shares present and will reconvene on October 29, 2025 at 12:00 p.m. ET.The meeting remains virtual via webcast and the record date of September 11, 2025 is unchanged. Stockholders who already voted need not act unless they wish to change their vote; those who have not voted are encouraged to vote before the new meeting date by following the instructions in the proxy materials.Additional meeting and voting details are available in the company's proxy statement filed with the SEC.

4 months ago

#REVB Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

$9.6 Million Cash Infusion: Revelation Biosciences Executes Strategic Warrant Deal with 5-Year Extension Biotech firm Revelation secures $9.6M through exercise of 4.35M warrants at $2.20/share. Deal includes new 5-year Class I warrants for 13.06M shares, pending stockholder approval.

6 months ago

#REVB Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

Breakthrough: Single Dose of Revelation Bio's Gemini Drug Normalizes Inflammation in Chronic Kidney Disease Gemini met primary safety endpoints in Phase 1b PRIME study, showing significant reduction in inflammatory markers across 40 CKD patients. Drug demonstrated durable rebalancing effect at cellular level.

6 months ago

#REVB Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

@alangreenstocks.bsky.social

6 months ago

Groundbreaking Results from #REVB Point to Relief for Millions buff.ly/TPo2bGR

0 0 0 0

Alan Green

6 months ago

Quoted Micro 1 September 2025 covers companies including - #PNIX #AAI #AJAX #APTA #BANK #CGNI #COG #DEBS #EEE #HRC #KR1 #LDG #LIFS #MACF #MWE #ORR #REVB #SWC #THX #TRCS #VRS #VULT #WSBN #ZYT

read: www.branduk.net/quoted-micro...

1 1 0 0

Justin Waite

@sharepickers.bsky.social

6 months ago

Can you put lipstick on a pig? Can you put lipstick on a pig?

Can you put lipstick on a pig?
audioboom.com/posts/876659...

Company’s Covered Today:
Revolution Beauty #REVB
Warpaint London #W7L

GET 25% OFF THE SHAREPICKERS INVESTMENT CLUB - OFFER ENDS IN 8 DAYS!

0 0 1 0

7 months ago

#REVB To Release Test Results This Quarter buff.ly/HeUwqFF

0 0 0 0

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 Revelation Biosciences (NASDAQ: REVB) reported its financial results for Q2 2025, highlighting key operational and financial developments. The company completed patient dosing in the PRIME Phase 1b Clinical Study of Gemini in CKD patients and secured $4 million in gross proceeds from a public offering in May 2025.Financial position shows $5.2 million in cash and cash equivalents as of June 30, 2025, down from $6.5 million at year-end 2024. The Q2 2025 net loss improved to $2.4 million ($(7.01) per share), compared to $8.4 million ($(246.27) per share) in Q2 2024. Current cash runway is expected to fund operations through December 2025.

7 months ago

#REVB Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

Revelation Bio's CKD Drug Trial Hits Major Milestone: Multiple Data Readouts Coming in Q3 Key safety and biomarker data expected Q3 2025 from completed Phase 1b PRIME study of Gemini drug in Stage 3-4 CKD patients. See full timeline.

7 months ago

#REVB Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

www.stocktitan.net/news/REVB/revelation-bio...

0 0 0 0

8 months ago

Investors Should Look at #REVB as Top-Line Results Approach buff.ly/2WpjIx7

0 0 0 0

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 Revelation Biosciences (NASDAQ: REVB) has announced a 1-for-3 reverse stock split effective July 7, 2025, following stockholder approval on June 23, 2025. The reverse split aims to increase the stock price to regain compliance with Nasdaq Capital Market's minimum bid listing requirements.The company will maintain its trading symbol "REVB" with a new CUSIP number 76135L705. Proportionate adjustments will be made to conversion and exercise prices of warrants, restricted stock units, stock options, and shares under equity incentive plans. Additionally, REVB announced that enrollment for its PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete this month, with topline data anticipated shortly after.Stockholders will see their shares automatically converted, with fractional shares rounded down. No action is required from registered stockholders or those holding shares through brokers.

8 months ago

#REVB Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

www.stocktitan.net/news/REVB/revelation-bio...

1 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping down in trading, Thu May 29th - #TATT #HUSA #RAPP #NTLA #MULN #FNGR #EOSE #REVB #BROG #CAL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0